These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.
135 related articles for article (PubMed ID: 25384962)
1. Mutant Enrichment with 3'-Modified Oligonucleotides (MEMO)-Quantitative PCR for Detection of NPM1 Mutations in Acute Myeloid Leukemia. Shin SY; Ki CS; Kim HJ; Kim JW; Kim SH; Lee ST J Clin Lab Anal; 2015 Sep; 29(5):361-5. PubMed ID: 25384962 [TBL] [Abstract][Full Text] [Related]
2. Rapid and highly specific screening for NPM1 mutations in acute myeloid leukemia. Oppliger Leibundgut E; Porret NA; Bienz Muggli M; Baumgartner H; Dahlhaus M; Baerlocher GM Ann Hematol; 2013 Jan; 92(2):173-7. PubMed ID: 23161387 [TBL] [Abstract][Full Text] [Related]
3. An allele-specific rt-PCR assay to detect type A mutation of the nucleophosmin-1 gene in acute myeloid leukemia. Ottone T; Ammatuna E; Lavorgna S; Noguera NI; Buccisano F; Venditti A; Giannì L; Postorino M; Federici G; Amadori S; Lo-Coco F J Mol Diagn; 2008 May; 10(3):212-6. PubMed ID: 18403613 [TBL] [Abstract][Full Text] [Related]
7. [Evaluation of methods for detection of NPM1 gene mutations in acute myeloid leukemia]. Li ZP; Zhang X; Zhao XM; Li QG; Chen YM; Lu QY Zhongguo Shi Yan Xue Ye Xue Za Zhi; 2011 Aug; 19(4):999-1004. PubMed ID: 21867632 [TBL] [Abstract][Full Text] [Related]
8. Detection of minimal residual disease in NPM1-mutated acute myeloid leukemia by next-generation sequencing. Salipante SJ; Fromm JR; Shendure J; Wood BL; Wu D Mod Pathol; 2014 Nov; 27(11):1438-46. PubMed ID: 24743218 [TBL] [Abstract][Full Text] [Related]
9. Monitoring minimal residual disease in acute myeloid leukaemia with NPM1 mutations by quantitative PCR: clonal evolution is a limiting factor. Papadaki C; Dufour A; Seibl M; Schneider S; Bohlander SK; Zellmeier E; Mellert G; Hiddemann W; Spiekermann K Br J Haematol; 2009 Feb; 144(4):517-23. PubMed ID: 19055671 [TBL] [Abstract][Full Text] [Related]
10. Development of a flow cytometric method to detect the presence of mutated nucleophosmin 1 in acute myeloid leukemia. Du Pisani LA; Shires K Hematol Oncol Stem Cell Ther; 2015 Sep; 8(3):106-14. PubMed ID: 26183674 [TBL] [Abstract][Full Text] [Related]
11. Comparison of RNA- and DNA-based methods for measurable residual disease analysis in NPM1-mutated acute myeloid leukemia. Pettersson L; Johansson Alm S; Almstedt A; Chen Y; Orrsjö G; Shah-Barkhordar G; Zhou L; Kotarsky H; Vidovic K; Asp J; Lazarevic V; Saal LH; Fogelstrand L; Ehinger M Int J Lab Hematol; 2021 Aug; 43(4):664-674. PubMed ID: 34053184 [TBL] [Abstract][Full Text] [Related]
12. Clinical implications of minimal residual disease monitoring by quantitative polymerase chain reaction in acute myeloid leukemia patients bearing nucleophosmin (NPM1) mutations. Chou WC; Tang JL; Wu SJ; Tsay W; Yao M; Huang SY; Huang KC; Chen CY; Huang CF; Tien HF Leukemia; 2007 May; 21(5):998-1004. PubMed ID: 17361227 [TBL] [Abstract][Full Text] [Related]
13. FMS-Like Tyrosine Kinase 3 (FLT3) and Nucleophosmin 1 (NPM1) in Iranian Adult Acute Myeloid Leukemia Patients with Normal Karyotypes: Mutation Status and Clinical and Laboratory Characteristics. Rezaei N; Arandi N; Valibeigi B; Haghpanah S; Khansalar M; Ramzi M Turk J Haematol; 2017 Dec; 34(4):300-306. PubMed ID: 28294102 [TBL] [Abstract][Full Text] [Related]
14. Clinical Laboratory Validation and Implementation of Quantitative, Real-Time PCR-based Detection of NPM1 Type A Mutation. Racchumi J; Tam W; Kluk MJ Clin Lab; 2020 Dec; 66(12):. PubMed ID: 33337831 [TBL] [Abstract][Full Text] [Related]
15. High NPM1 mutant allele burden at diagnosis correlates with minimal residual disease at first remission in de novo acute myeloid leukemia. Patel SS; Pinkus GS; Ritterhouse LL; Segal JP; Dal Cin P; Restrepo T; Harris MH; Stone RM; Hasserjian RP; Weinberg OK Am J Hematol; 2019 Aug; 94(8):921-928. PubMed ID: 31148220 [TBL] [Abstract][Full Text] [Related]
16. Molecular response assessment by quantitative real-time polymerase chain reaction after induction therapy in NPM1-mutated patients identifies those at high risk of relapse. Hubmann M; Köhnke T; Hoster E; Schneider S; Dufour A; Zellmeier E; Fiegl M; Braess J; Bohlander SK; Subklewe M; Sauerland MC; Berdel WE; Büchner T; Wörmann B; Hiddemann W; Spiekermann K Haematologica; 2014 Aug; 99(8):1317-25. PubMed ID: 24816240 [TBL] [Abstract][Full Text] [Related]
17. Quantification of rare NPM1 mutation subtypes by digital PCR. Bacher U; Dicker F; Haferlach C; Alpermann T; Rose D; Kern W; Haferlach T; Schnittger S Br J Haematol; 2014 Dec; 167(5):710-4. PubMed ID: 25039748 [No Abstract] [Full Text] [Related]
18. Correlation of NPM1 Type A Mutation Burden With Clinical Status and Outcomes in Acute Myeloid Leukemia Patients With Mutated NPM1 Type A. Jo SY; Park SH; Kim IS; Yi J; Kim HH; Chang CL; Lee EY; Cho YU; Jang S; Park CJ; Chi HS Ann Lab Med; 2016 Sep; 36(5):399-404. PubMed ID: 27374703 [TBL] [Abstract][Full Text] [Related]
19. Minimal Residual Disease Monitoring of Acute Myeloid Leukemia by Massively Multiplex Digital PCR in Patients with NPM1 Mutations. Mencia-Trinchant N; Hu Y; Alas MA; Ali F; Wouters BJ; Lee S; Ritchie EK; Desai P; Guzman ML; Roboz GJ; Hassane DC J Mol Diagn; 2017 Jul; 19(4):537-548. PubMed ID: 28525762 [TBL] [Abstract][Full Text] [Related]
20. [Simultaneous detection of FLT3-ITD and NPM1 gene mutations in acute myeloid leukemia by double PCR]. Zhang ZC; Lu QY; Zhao JN; Chen YM; Li ZP Zhongguo Shi Yan Xue Ye Xue Za Zhi; 2011 Jun; 19(3):717-20. PubMed ID: 21729557 [TBL] [Abstract][Full Text] [Related] [Next] [New Search]